Share

Moderna has 4th dose of the COVID-19 vaccine booster shot

WASHINGTON (AP) — Drugmaker Moderna asked the Food and Drug Administration on Thursday to authorize a fourth shot of its COVID-19 vaccine as a booster dose for all adults.

Read Christopher Williams hopeful of vaccine mandate removal

The request is broader than rival pharmaceutical company Pfizer’s request earlier this week for the regulator to approve a booster shot for all seniors.

In a press release, the company said its request for approval for all adults was made “to provide flexibility” to the Centers for Disease Control and Prevention and medical providers to determine the “appropriate use” of a second booster dose of the mRNA vaccine, “including for those at higher risk of COVID-19 due to age or comorbidities.”

Follow us on Twitter

U.S. officials have been laying the groundwork to deliver additional booster doses to shore up the vaccines’ protection against serious disease and death from COVID-19. The White House has been sounding the alarm that it needs Congress to “urgently” approve more funding for the federal government to secure more doses of the COVID-19 vaccines, either for additional booster shots or variant-specific immunizations.

U.S. health officials currently recommend a primary series of two doses of the Moderna vaccine and a booster dose months later.

Moderna said its request for an additional dose was based on “recently published data generated in the United States and Israel following the emergence of Omicron.”

Visit our homepage for more daily stories!

On Tuesday, Pfizer and its partner BioNTech asked U.S. regulators to authorize an additional booster dose of their COVID-19 vaccine for seniors, saying data from Israel suggests older adults would benefit.

Moderna seeks FDA authorization for 4th dose of COVID shot  The Associated Press – en Español

Also read: Pfizer Pushes Second Booster Shot As Effectiveness Wanes

Pfizer plans to ask U.S. regulators to grant emergency use authorization for a second booster of its COVID-19 vaccine, CEO Albert Bourla said March 11.

“Clearly there is a need in an environment of Omicron to boost the immune response,” Bourla said on CNBC’s “Squawk Box.”

Pfizer’s vaccine waned over time in protection against both infection and hospitalization when the Delta variant of the virus that causes COVID-19 was dominant in the United States, real-world data and studies showed. The issue has grown more pronounced since Omicron continue reading.

Like and share this article if you enjoyed! 🙂


Share

By Cleo

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: